(Reuters) -Exposure to wildfire smoke may increase lung cancer patients' risk of dying from their disease, particularly among ...

In its first global phase 3 readout, Akeso and Summit Therapeutics’ closely watched PD-1xVEGF bispecific antibody ivonescimab ...

The BLA seeking accelerated approval for patritumab deruxtecan in previously treated, locally advanced EGFR-mutated NSCLC in ...

A molecular test identified patients with high-risk early lung cancer who significantly benefitted from adjuvant chemotherapy ...

Maintenance therapy with lurbinectedin (lurbi) and atezolizumab (atezo) helps some patients with extensive-stage small cell ...

A recently-approved treatment could take a BiTE out of small cell lung cancer by using a person's own body to fight back.

Patients with extensive-stage SCLC often respond to induction therapy, but the disease tends to progress rapidly after cytotoxic therapy ends, said Jared Weiss, MD, of the University of North Carolina ...

Researchers from The University of Texas MD Anderson Cancer Center have identified a new biomarker, TTF-1, that was ...

Patritumab deruxtecan was unable to significantly improve overall survival in patients with locally advanced or metastatic ...

Breathing in wildfire pollution may make it harder for people with lung cancer to survive, according to a new study from UC ...

Patients with extensive-stage small cell lung cancer (SCLC) experienced clinically meaningful benefits with lurbinectedin ...

Findings seen for patients with extensive-stage small cell lung cancer, following standard induction therapy.